The Namibia Medicines Regulatory Council (NMRC) has directed Fabupharm Namibia Ltd to recall all oral liquid medicinal products after inspections revealed manufacturing deficiencies in the company’s production processes.

According to a statement released by the Office of the Registrar of Medicines, the NMRC issued the recall instructions on 2 June 2025. 

The directive includes a temporary halt to manufacturing on the affected production line until identified issues are resolved and brought in line with regulatory standards.

The action follows a routine inspection aimed at evaluating compliance with good manufacturing practices. 

The statement says that inspectors noted several shortcomings in the oral liquid dosage block, prompting the council to mandate both corrective and preventive measures.